tarlatamab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
monoclonal antibodies 5821 None

Description:

MoleculeDescription

Molfile

Synonyms:

  • tarlatamab
  • tarlatamab-dlle
  • imdelltra
  • AMG 757
Tarlatamab is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager. Tarlatamab binds to DLL3-expressing tumor cells and CD3-expressing T cells, resulting in T-cell activation and cytokine release, leading to lysis of DLL3-expressing cells.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
May 16, 2024 FDA Amgen Inc.
Dec. 27, 2024 PMDA Amgen K.K.
May 29, 2026 EMA Amgen Europe B.V.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 701.41 63.99 126 513 27847 90599961
Immune effector cell-associated neurotoxicity syndrome 463.15 63.99 71 568 5697 90622111
Off label use 81.29 63.99 64 575 1102188 89525620

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 898.70 49.69 203 758 44324 42576050
Immune effector cell-associated neurotoxicity syndrome 320.82 49.69 67 894 9394 42610980
Metastases to central nervous system 92.39 49.69 25 936 10330 42610044
Small cell lung cancer metastatic 89.12 49.69 14 947 382 42619992
Taste disorder 78.80 49.69 22 939 10185 42610189
Small cell lung cancer 65.83 49.69 14 947 2081 42618293
Pyrexia 51.58 49.69 53 908 393989 42226385

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 1085.83 51.94 224 910 70082 110518083
Immune effector cell-associated neurotoxicity syndrome 368.02 51.94 71 1063 14711 110573454
Metastases to central nervous system 121.14 51.94 31 1103 22786 110565379
Small cell lung cancer 95.31 51.94 18 1116 3254 110584911
Small cell lung cancer metastatic 86.20 51.94 13 1121 606 110587559
Disease progression 60.31 51.94 35 1099 243999 110344166
Taste disorder 59.20 51.94 23 1111 65364 110522801
Pyrexia 55.28 51.94 56 1078 898209 109689956

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX33 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
MeSH PA D000970 Antineoplastic Agents
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FX Other monoclonal antibodies and antibody drug conjugates 29 drugs
amivantamabbelantamab mafodotinblinatumomabbrentuximab vedotincatumaxomabdatopotamab deruxtecanelotuzumabelranatamabenfortumab vedotinepcoritamabgemtuzumab ozogamicinglofitamab show all 29 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Small cell lung cancer indication 254632001 DOID:5409




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
T-cell surface glycoprotein CD3 Surface antigen ANTIBODY BINDING Kd 7.84 DRUG LABEL DRUG LABEL
Delta-like protein 3 Surface antigen ANTIBODY BINDING Kd 9.19 DRUG LABEL DRUG LABEL

External reference:

IDSource
2307488-83-9 SECONDARY_CAS_RN
CHEMBL5095292 ChEMBL_ID
C000722655 MESH_SUPPLEMENTAL_RECORD_UI
DB17256 DRUGBANK_ID
4043167 VANDF
4043168 VANDF
C5446797 UMLSCUI
CHEBI:758866 CHEBI
11420 INN_ID
385584 MMSL
42862 MMSL
d10189 MMSL
019759 NDDF
12969 IUPHAR_LIGAND_ID
74X82ST8Q1 UNII
2682954 RXNORM
92911000087102 SNOMEDCT_US
D12234 KEGG_DRUG

Pharmaceutical products:

None